BOSTON, October 27, 2020: Morgan Lewis represented biotechnology company Replimune Group Inc. in its public offering of 5,625,000 shares of common stock and pre-funded warrants to purchase 1,562,500 shares of its common stock. The offering closed on October 26.
Nasdaq-listed Replimune is developing oncolytic immuno-gene therapies derived from its Immulytic platform intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released.
Morgan Lewis partner Timothy Corbett and associates Benjamin Stein and Davis Truslow represented Replimune.